E-LIB Suche - Ergebnisse für: Carlo-Stella, C.

1

119P Long-term safety evaluation of roginolisib (formerly I..:

Di Giacomo, A.M. ; Mason, P. ; Snijder, R....
ESMO Open. 8 (2023) 1 - p. 101065 , 2023

Link: https://doi.org/10.1016/..

2

53P Characterization of the non-ATP competitive PI3Kdelta i..:

Bertoni, F. ; Tarantelli, C. ; Spriano, F....
ESMO Open. 8 (2023) 1 - p. 100911 , 2023

Link: https://doi.org/10.1016/..

3

P39 DEDALO: PHASE II STUDY OF DARATUMUMAB PLUS POMALIDOMIDE..:

Montefusco, V. ; Cafro, A.M. ; Margiotta Casaluci, G....
HemaSphere. 7 (2023) S2 - p. 32-33 , 2023

Link: https://doi.org/10.1097/..

4

131P Safety and clinical efficacy of roginolisib (IOA-244):..:

Di Giacomo, A.M. ; Simonelli, M. ; Santangelo, F....
Immuno-Oncology and Technology. 20 (2023) - p. 100603 , 2023

Link: https://doi.org/10.1016/..

5

192P Safety and clinical activity of IOA-244: A highly sele..:

Di Giacomo, A.M. ; Santangelo, F. ; Amato, G....
Immuno-Oncology and Technology. 16 (2022) - p. 100304 , 2022

Link: https://doi.org/10.1016/..

6

S220: GLOFITAMAB INDUCES DURABLE COMPLETE REMISSIONS AND HA..:

Dickinson, M. ; Carlo-Stella, C. ; Morschhauser, F....
HemaSphere. 6 (2022) - p. 121-122 , 2022

Link: https://doi.org/10.1097/..

7

P1210: IMMUNE CORRELATES OF RESPONSE TO GLOFITAMAB: BIOMARK..:

Piccione, E. C. ; Belousov, A. ; Hamidi, H....
HemaSphere. 6 (2022) - p. 1096-1097 , 2022

Link: https://doi.org/10.1097/..

8

PB2118: PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE ..:

Hamadani, M. ; Linhares, Y. ; Gandhi, M. D....
HemaSphere. 6 (2022) - p. 1989-1990 , 2022

Link: https://doi.org/10.1097/..

9

S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN..:

Carlo-Stella, C. ; Ansell, S. ; Zinzani, P. L...
HemaSphere. 6 (2022) - p. 102-103 , 2022

Link: https://doi.org/10.1097/..

10

PB2119: LONG-TERM SURVIVAL PROJECTIONS OF LONCASTUXIMAB TES..:

Hamadani, M. ; Graham, C. N. ; Liao, L....
HemaSphere. 6 (2022) - p. 1990-1991 , 2022

Link: https://doi.org/10.1097/..

11

Correction to: Risk of relapse after anti-PD1 discontinuati..:

Manson, G. ; Brice, P. ; Herbaux, C....
European Journal of Nuclear Medicine and Molecular Imaging. 48 (2021) 5 - p. 1699-1700 , 2021

Link: https://doi.org/10.1007/..

12

Risk of relapse after anti-PD1 discontinuation in patients ..:

Manson, G. ; Brice, P. ; Herbaux, C....
European Journal of Nuclear Medicine and Molecular Imaging. 48 (2020) 4 - p. 1144-1153 , 2020

Link: https://doi.org/10.1007/..

13

Haploidentical transplantation with post-infusion cyclophos..:

Castagna, L ; Bramanti, S ; Devillier, R...
Bone Marrow Transplantation. 52 (2017) 5 - p. 683-688 , 2017

Link: https://doi.org/10.1038/..

14

Erratum: Haploidentical transplantation with post-infusion ..:

Castagna, L ; Bramanti, S ; Devillier, R...
Bone Marrow Transplantation. 52 (2017) 5 - p. 797-797 , 2017

Link: https://doi.org/10.1038/..

15

The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Ve..:

Locatelli, S L ; Careddu, G ; Inghirami, G...
Leukemia. 30 (2016) 12 - p. 2402-2405 , 2016

Link: https://doi.org/10.1038/..